SPOTLIGHT: Talecris may be sold
Almost a year after filing plans for a $1 billion IPO for Talecris Biotherapeutics, Cerberus and partner Ampersand Ventures may instead pursue a sale of the blood plasma product business. And Australia's CSL may be in the running. The blood plasma product business has been rapidly consolidating. Talecris said last year that three companies controlled 82 percent of the U.S. market. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
